One Health approach to Rift Valley fever vaccine development

Jeroen Kortekaas

doi:10.1016/j.antiviral.2014.03.008

One Health approach to Rift Valley fever vaccine development

Antiviral Res. 2014 Jun:106:24-32. doi: 10.1016/j.antiviral.2014.03.008. Epub 2014 Mar 26.

Author

Jeroen Kortekaas¹

Affiliation

¹ Department of Virology, Central Veterinary Institute, Part of Wageningen University and Research Centre, P.O. Box 65, 8200 AB Lelystad, The Netherlands. Electronic address: Jeroen.kortekaas@wur.nl.

PMID: 24681125
DOI: 10.1016/j.antiviral.2014.03.008

Abstract

Since its discovery in the 1930s, Rift Valley fever virus (RVFV) spread across the African continent and invaded the Arabian Peninsula and several islands off the coast of Southeast Africa. The virus causes recurrent outbreaks in these regions, and its continued spread is of global concern. Next-generation veterinary vaccines of improved efficacy and safety are being developed that can soon be used for the widespread vaccination of livestock. However, due to regulatory and economic challenges, vaccine manufacturers have been reluctant to develop a human vaccine. Recent innovations in veterinary vaccinology, animal models and licensing strategies can now be used to overcome these hurdles. This paper reviews the historical impact of RVFV on human health and proposes strategies to develop and license a next-generation vaccine for both animals and humans.

Keywords: Human; One Health; Rift Valley fever virus; Vaccine; Veterinary.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Drug Approval
Drug Discovery / methods*
Humans
Livestock
Rift Valley Fever / prevention & control*
Rift Valley fever virus / immunology*
Viral Vaccines / immunology*
Viral Vaccines / isolation & purification*

Substances

Viral Vaccines